Q3 2026 Cipla Ltd Earnings Call Transcript
Key Points
- Cipla Ltd (BOM:500087) reported strong performance in its One India business with a 10% year-on-year growth, driven by robust growth in key therapies such as respiratory, anti-diabetes, cardiac, and urology.
- The company achieved significant milestones in its respiratory segment, crossing INR5,000 crores in IPM and outperforming therapy IPM growth by 400 basis points.
- Cipla Ltd (BOM:500087) entered into strategic agreements with Pfizer and acquired Inspira Health Sciences, enhancing its portfolio and distribution network.
- The company launched Afrezza, India's first inhaled rapid-acting insulin, and Yurpeak, a modern therapy for obesity and Type 2 diabetes, expanding its diabetes portfolio.
- Cipla Ltd (BOM:500087) maintained its number one position in the US albuterol MDI market with a 22% market share and is preparing for significant respiratory launches, including generic Advair, to drive future growth.
- Cipla Ltd (BOM:500087) faced a decline in EBITDA margin to 17.7%, primarily due to lower generic Revlimid revenues.
- The company experienced supply challenges and increased competition in North America, impacting its revenue growth.
- Lanreotide production was temporarily paused due to US FDA inspection observations, causing potential short-term disruption in supply.
- The company's gross margin was affected by a decline in lenalidomide sales and product mix, along with increased R&D material costs.
- Cipla Ltd (BOM:500087) revised its US revenue guidance downward due to the anticipated impact of lanreotide supply issues.
Ladies and gentlemen, good day, and welcome to Cipla Limited Q3 FY26 earnings conference call. We have with us today from the management, Mr. Umang Vohra, MD and Global CEO; Mr. Achin Gupta, MD and Global CEO Designate; Mr. Ashish Adukia, Global CFO; Mr. Diksha Maheshwari, Head, Investor Relations.
(Operator Instructions) Please note that this conference is being recorded. I now hand the conference over to Ms. Diksha Maheshwari, Head Investor Relations. Thank you, and over to you, Ms. Maheshwari.
Thank you, Andrew. Good afternoon, and a very warm welcome to Cipla's Q3 FY26 earnings call. I'm Diksha Maheshwari from the Investor Relations team at Cipla.
Let me draw your attention to the fact that on this call, our discussion will include certain forward-looking statements, which are predictions, projections, or other estimates about future events. These estimates reflect management's current expectations of the future performance of the company.
Please note that these
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
